Overview:
Newborn Screening Panel 8 ProfileIntroduction: The Newborn Screening Panel 8 Profile is a diagnostic tool designed to screen for congenital metabolic disorders using dried blood spot samples. Associated with conditions like phenylketonuria and congenital hypothyroidism, these disorders present with developmental delay, jaundice, and severe complications if untreated, particularly in newborns with suspected metabolic issues. Per the 2023 Biochemistry guidelines, the test employs biochemistry with HPLC-MS/MS technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for newborn screening in clinical settings. This diagnostic falls under newborn screening and targets newborns with suspected congenital metabolic disorders, addressing the challenge of accurate metabolite assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood spot-based approach ensures reliable detection.
Other Names: Newborn Scr 8 Pfl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: Introduced in the 1960s by pediatric labs, this test advanced newborn metabolic screening.
Purpose: The test screens for 11 parameters including phenylalanine to guide metabolic assessment, assess congenital disorders, and inform treatment and prevention strategies.
Test Parameters: 1. Phenylalanine, 2. Tyrosine, 3. Leucine, 4. Methionine, 5. Free Carnitine, 6. C3 (Propionylcarnitine), 7. C5 (Isovalerylcarnitine), 8. TSH, 9. 17-OH Progesterone, 10. GALT, 11. Biotinidase.
Pretest Condition: No fasting required; newborns should be screened within the first few days of life as per protocol.
Specimen: 5â€"6 drops dried blood spot on filter paper, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 30 days with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 60 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not specified, room temperature storage recommended to preserve analyte integrity.
Medical History: Parents should provide details on newborn health, prior family history of metabolic disorders, or any observed developmental concerns.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated congenital disorders including intellectual disability, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using HPLC-MS/MS and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or improper sample collection can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible congenital metabolic disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms emerge.
Specialist Consultation: Pediatricians or specialists in metabolic disorders should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: Enzyme assays or genetic testing for confirmation.
Test Limitations: The test may produce false negatives in early stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Biochemistry Guidelines 2023, Journal of Pediatrics 2024, Chemistry 2025.
